The aim of this review was to provide the reader with an overview of PDE4 targeting compounds that have reached clinical trials in the last ten years, since the first PDE4 inhibitor was marketed, with a focus on those most recently developed for respiratory, skin and neurological disorders. Here, PDE4A is linked to nervous system disorder.